<DOC>
	<DOCNO>NCT01451437</DOCNO>
	<brief_summary>This study MK-8242 alone combination cytarabine adult participant refractory recurrent acute myelogenous leukemia ( AML ) . The study 2 Arms . Arm A participant refractory recurrent AML consider ineligible standard chemotherapy . In Part 1 Arm A , participant receive MK-8242 monotherapy escalate dos determine recommend phase 2 dose [ RP2D ] . In Part 2 , participant receive monotherapy MK-8242 confirm RP2D ass preliminary efficacy . Arm B participant recurrent AML follow initial complete remission ( CR ) CR incomplete marrow recovery ( CRi ) 6 12 month duration . In Part 1 Arm B , participant receive MK-8242 escalating dos + cytarabine determine RP2D combination cytarabine . In Part 2 , participant receive MK-8242 + cytarabine confirm RP2D ass preliminary efficacy . The pharmacokinetics MK-8242 study arm . With Amendment 4 ( 22 August 2013 ) 21-day dose cycle add , MK-8242 give Days 1-7 21-day cycle monotherapy combination therapy arm ; data Arm A used determine whether participant receives 21-day 28-day therapy Arm B .</brief_summary>
	<brief_title>Study MK-8242 Alone Combination With Cytarabine Participants With Acute Myelogenous Leukemia ( P07649 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion criterion : For Arm A Part 1 ( monotherapy/dose escalation ) : refractory recurrent AML , appropriate candidate standard therapy For Arm A Part 2 ( monotherapy/dose confirmation/cohort expansion ) : refractory recurrent AML , appropriate candidate standard therapy , wild type p53 gene mutation analysis For Arm B Part 1 ( combination therapy/dose escalation ) : recurrent AML achieve initial CR CRi 612 month duration age ≥18 year old &lt; 70 year old For Arm B Part 2 ( combination therapy/dose confirmation/cohort expansion ) : recurrent AML achieve initial CR CRi 612 month duration , age ≥18 year old &lt; 70 year old , wild type P53 gene mutation analysis Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Arm A , 0 1 Arm B Negative pregnancy test within 72 hour first dose study medication Female participant male participant partner childbearing potential must agree abstain sexual intercourse use acceptable method contraception study 90 day follow last dose study therapy Adequate organ function Recovered effect prior surgery , radiotherapy antineoplastic treatment , exception alopecia Must able swallow , retain , absorb oral medication oral nutrition Must follow appropriate washout period prohibit treatment Exclusion criterion : Active malignancy AML Leptomeningeal leukemia require intrathecal therapy For Arm A B , Part 1 : history myelodysplastic syndrome ( MDS ) For Arm A B , Part 2 : AML background MDS may include Isolated extramedullary leukemia without also meet bone marrow criterion acute leukemia AML blast crisis chronic myelogenous leukemia ( CML ) Bone marrow transplant active graftversus host disease ( GVHD ) receive immunosuppressive therapy Uncontrolled active infection require systemic treatment Clinically significant hepatitis Screening , hepatitis C antibody positive , hepatitis B surface antigen positive , human immunodeficiency virus ( HIV ) seropositive Persistent , unresolved , drugrelated toxicity Breastfeeding , pregnant , intend become pregnant intend breast feed study positive pregnancy test Screening A person participate clinical study potentially therapeutic agent receive another investigational product within 5 halflives ( halflife know ) 28 day ( halflife unknown ) prior Day 1 cycle 1 A participant , within past 6 month , follow : myocardial infarction , coronary/peripheral artery bypass graft , cerebrovascular accident , transient ischemic attack , uncontrolled seizure disorder ( i.e. , seizure within past 6 month ) A participant , time Screening , present : unstable uncontrolled angina , New York Heart Association ( NYHA ) class III IV congestive heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia clinically significant electrocardiogram ( ECG ) abnormality Known bleeding disorder , e.g . hemophilia disseminate intravascular coagulopathy anticoagulation therapy For Arm B : Known hypersensitivity cytarabine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>